UP!
|
Type
|
Subsidiary of AbbVie |
|---|---|
| Traded as | Formerly NASDAQ: PCYC |
| Industry | Biopharmaceutical |
| Founded | 1991 (1991) |
| Founders | Jonathan Sessler, Richard A. Miller |
| Headquarters | Sunnyvale, California |
|
Area served
|
Worldwide |
|
Key people
|
Robert Duggan, former CEO and Chairman |
| Parent | AbbVie |
| Website | pharmacyclics |
Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. Its primary focus is upon the development of "novel therapies for the treatment of cancer and immune-mediated diseases." In 2017, Xynomic Pharmaceuticals acquired all global rights to abexinostat from Pharmacyclics.
In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire oncology firm Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity. The merger is expected to close in mid-2015.
Duggan will receive over $3.55 billion from the sale of Pharmacyclics to AbbVie in "one of the biggest paydays ever from the buyout of a publicly held company."
As CEO and Chairman of Pharmacyclics since 2008, Robert Duggan has opted not to receive compensation from the company.
| 2015-05-29 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-04-20 | Reiterated Rating | BMO Capital Markets | Positive | |
| 2015-03-06 | Reiterated Rating | Credit Suisse | Neutral | |
| 2015-03-06 | Downgrade | Leerink Swann | Outperform to Market Perform | |
| 2015-03-06 | Boost Price Target | WallachBeth Capital | Hold | $222.00 to $261.00 |
| 2015-03-06 | Reiterated Rating | Credit Suisse Group AG | Neutral | |
| 2015-03-05 | Set Price Target | Piper Jaffray | Hold | $184.00 |
| 2015-03-05 | Downgrade | Nomura | Buy to Neutral | $196.00 to $261.25 |
| 2015-03-05 | Downgrade | Wells Fargo & Co. | Outperform to Market Perform | $261.25 |
| 2015-03-05 | Downgrade | BTIG Research | Buy to Neutral | |
| 2015-03-05 | Boost Price Target | RBC Capital | Sector Perform | $145.00 to $261.00 |
| 2015-03-05 | Downgrade | Wells Fargo | Outperform to Market Perform | $261.25 |
| 2015-03-05 | Set Price Target | Piper Jaffray Cos. | Hold | $184.00 |
| 2015-03-05 | Downgrade | Nomura Holdings Inc. | Buy to Neutral | $196.00 to $261.25 |
| 2015-03-05 | Boost Price Target | Royal Bank Of Canada | Sector Perform | $145.00 to $261.00 |
| 2015-03-03 | Downgrade | Wedbush | Outperform to Neutral | $225.00 to $234.00 |
| 2015-03-02 | Boost Price Target | Leerink Swann | Outperform to Outperform | $204.00 to $240.00 |
| 2015-02-27 | Downgrade | Goldman Sachs | Hold | $184.00 |
| 2015-02-27 | Downgrade | Credit Suisse | Hold | $233.00 |
| 2015-02-27 | Downgrade | Goldman Sachs Group Inc. | Hold | $184.00 |
| 2015-02-26 | Downgrade | Goldman Sachs | Buy to Neutral | $217.82 to $184.00 |
| 2015-02-26 | Boost Price Target | Robert W. Baird | $240.00 | |
| 2015-02-26 | Downgrade | Credit Suisse | Outperform to Neutral | $163.00 to $223.00 |
| 2015-02-26 | Downgrade | WallachBeth Capital | Buy to Hold | $228.00 |
| 2015-02-25 | Downgrade | Deutsche Bank | Buy to Hold | $235.00 |
| 2015-02-25 | Downgrade | Deutsche Bank AG | Buy to Hold | $235.00 |
| 2015-02-19 | Reiterated Rating | Stifel Nicolaus | Hold | |
| 2015-02-19 | Boost Price Target | Deutsche Bank | Buy | $180.00 to $205.00 |
| 2015-02-19 | Boost Price Target | Leerink Swann | Outperform | $153.00 to $204.00 |
| 2015-02-19 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $152.00 to $173.00 |
| 2015-02-19 | Upgrade | Nomura | Neutral to Buy | $195.00 to $196.00 |
| 2015-02-19 | Downgrade | Roth Capital | Buy to Neutral | $189.00 to $187.00 |
| 2015-01-29 | Boost Price Target | Roth Capital | Buy | $188.00 to $189.00 |
| 2015-01-14 | Set Price Target | Roth Capital | Buy | $188.00 |
| 2015-01-14 | Boost Price Target | Citigroup Inc. | Buy | $145.00 to $155.00 |
| 2015-01-13 | Set Price Target | Robert W. Baird | Buy | $173.00 |
| 2015-01-13 | Set Price Target | RBC Capital | Hold | $130.00 |
| 2015-01-06 | Initiated Coverage | BTIG Research | Buy | $225.00 |
| 2015-01-05 | Set Price Target | Roth Capital | Buy | $188.00 |
| 2015-01-05 | Downgrade | Nomura | Buy to Neutral | $175.00 to $158.00 |
| 2014-11-05 | Reiterated Rating | JMP Securities | Market Outperform | $200.00 to $204.00 |
| 2014-11-05 | Reiterated Rating | Nomura | Buy | $158.00 to $175.00 |
| 2014-11-05 | Reiterated Rating | Morgan Stanley | Equal Weight | $103.00 to $111.00 |
| 2014-10-27 | Reiterated Rating | Nomura | Buy | $158.00 |
| 2014-10-17 | Reiterated | ROTH Capital | Buy | $185 to $188 |
| 2014-10-15 | Initiated Coverage | Citigroup Inc. | Buy | $145.00 |
| 2014-10-14 | Boost Price Target | Roth Capital | Buy | $183.00 to $185.00 |
| 2014-09-16 | Boost Price Target | William Blair | $186.00 | |
| 2014-09-11 | Reiterated Rating | Morgan Stanley | Equal Weight | $101.00 |
| 2014-09-04 | Initiated Coverage | SunTrust | Neutral | $140.00 |
| 2014-09-04 | Initiated Coverage | SunTrust Banks Inc. | Neutral | $140.00 |
| 2014-08-05 | Boost Price Target | William Blair | Outperform | $150.00 to $180.00 |
| 2014-08-01 | Upgrade | WallachBeth | Hold to Buy | |
| 2014-08-01 | Reiterated Rating | Deutsche Bank | Buy | $180.00 |
| 2014-08-01 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $150.00 to $152.00 |
| 2014-08-01 | Boost Price Target | RBC Capital | $95.00 to $100.00 | |
| 2014-08-01 | Reiterated Rating | Nomura | Buy | $174.00 to $177.00 |
| 2014-08-01 | Boost Price Target | Morgan Stanley | $94.00 to $101.00 | |
| 2014-08-01 | Boost Price Target | JMP Securities | Market Outperform | $191.00 to $200.00 |
| 2014-08-01 | Boost Price Target | Credit Suisse | $121.00 to $163.00 | |
| 2014-08-01 | Upgrade | WallachBeth Capital | Hold to Buy | $160.00 |
| 2014-07-29 | Upgrade | Leerink Swann | Market Perform to Outperform | $102.00 to $142.00 |
| 2014-07-28 | Reiterated Rating | Roth Capital | Buy | |
| 2014-07-14 | Lower Price Target | Nomura | $177.00 to $174.00 | |
| 2014-06-30 | Reiterated Rating | Credit Suisse | Outperform | $121.00 |
| 2014-05-27 | Downgrade | RBC Capital | Outperform to Sector Perform | $110.00 to $95.00 |
| 2014-05-27 | Lower Price Target | Morgan Stanley | Equal Weight | $100.00 to $95.00 |
| 2014-05-05 | Lower Price Target | Nomura | $186.00 to $177.00 | |
| 2014-05-05 | Lower Price Target | RBC Capital | Outperform | $150.00 to $110.00 |
| 2014-05-05 | Lower Price Target | Morgan Stanley | Equal Weight | $120.00 to $100.00 |
| 2014-05-02 | Downgrade | Piper Jaffray | Overweight to Neutral | |
| 2014-04-21 | Upgrade | Ned Davis Research | Sell to Neutral | |
| 2014-03-26 | Initiated Coverage | Morgan Stanley | Equal Weight | $120.00 |
| 2014-02-24 | Boost Price Target | Roth Capital | $183.00 | |
| 2014-02-21 | Boost Price Target | Deutsche Bank | Buy | $170.00 to $180.00 |
| 2014-02-21 | Set Price Target | JMP Securities | $163.00 to $191.00 | |
| 2014-02-21 | Boost Price Target | Nomura | $166.00 | |
| 2014-02-21 | Boost Price Target | Robert W. Baird | $163.00 to $173.00 | |
| 2014-02-13 | Boost Price Target | Roth Capital | $166.00 | |
| 2014-01-08 | Initiated Coverage | Nomura | Buy | |
| 2013-12-18 | Initiated | WallachBeth | Hold | $108 |
| 2013-12-18 | Initiated Coverage | WallachBeth Capital | Hold | $108.00 |
| 2013-12-03 | Boost Price Target | RBC Capital | $125.00 to $150.00 | |
| 2013-11-26 | Initiated Coverage | Piper Jaffray | Overweight | $160.00 |
| 2013-11-14 | Boost Price Target | Roth Capital | Buy | $144.00 to $151.00 |
| 2013-11-14 | Boost Price Target | JMP Securities | Market Outperform | $135.00 to $163.00 |
| 2013-11-14 | Reiterated Rating | Wedbush | Outperform | $165.00 |
| 2013-11-08 | Boost Price Target | Robert W. Baird | Outperform | $123.00 to $132.00 |
| 2013-10-30 | Reiterated Rating | Goldman Sachs | Buy | $170.00 |
| 2013-10-30 | Boost Price Target | Roth Capital | $144.00 | |
| 2013-10-11 | Upgrade | Goldman Sachs | Neutral to Buy | $123.14 to $170.00 |
| 2013-10-04 | Initiated Coverage | Wells Fargo & Co. | Outperform | |
| 2013-10-04 | Initiated Coverage | Wells Fargo | Outperform | |
| 2013-09-26 | Initiat | |||
| 2013-09-26 | Initiated Coverage | JPMorgan Chase & Co. | Overweight to Overweight | $142.00 to $170.00 |
| 2013-09-26 | Initiated Coverage | Deutsche Bank | Buy | $170.00 |
| 2013-09-25 | Boost Price Target | JMP Securities | Market Outperform | $125.00 to $135.00 |
| 2013-09-23 | Reiterated Rating | Lazard Capital Markets | Buy | $141.00 |
| 2013-09-23 | Initiated Coverage | William Blair | Outperform | $143.00 |
| 2013-09-23 | Boost Price Target | Morgan Stanley | Equal Weight | $94.00 to $103.00 |
| 2013-09-18 | Boost Price Target | Goldman Sachs | Buy | $102.00 to $111.00 |
| 2012-12-12 | Reiterated | Wedbush | Outperform | $93 to $110 |
| 2012-05-17 | Reiterated | Rodman & Renshaw | Mkt Outperform | $22 to $40 |
| 2012-05-17 | Reiterated | Needham | Buy | $23 to $32 |
| 2011-12-07 | Initiated | Rodman & Renshaw | Mkt Outperform | $20 |
| 2010-06-07 | Reiterated | Wedbush | Outperform | $8 to $16 |
| 2010-04-14 | Reiterated | Roth Capital | Buy | $7 to $11 |
| 2010-02-12 | Downgrade | BWS Financial | Buy to Hold |
| 2015-05-29 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-04-20 | Reiterated Rating | BMO Capital Markets | Positive | |
| 2015-03-06 | Reiterated Rating | Credit Suisse | Neutral | |
| 2015-03-06 | Downgrade | Leerink Swann | Outperform to Market Perform | |
| 2015-03-06 | Boost Price Target | WallachBeth Capital | Hold | $222.00 to $261.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In PCYC 3 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Placemark Investments, Inc. | 15250 |
| BAIRD ROBERT W & CO INC /WI/ | 920 |
| BOSTON PRIVATE BANK & TRUST CO | 100 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Hemmi Gregory VP Chemical Operations | 0.05% (38004) | PCYC / |
| Outten Matthew VP, Commercial Operations | 0.01% (10758) | PCYC / |
| Sjovall Boultbee Paula S EVP, Sales and Marketing | 0.01% (9653) | PCYC / |
| Erdtmann Rainer M Sr. VP, IR and Admin | 0.01% (5701) | PCYC / |
UM